Kāhu is developing an artificial intelligence platform that analyzes dermatological images from one of the largest skin lesion databases to detect early signs of melanoma and other skin cancers. This technology enhances clinical diagnosis and management, providing healthcare professionals with a reliable tool to improve patient outcomes in skin cancer detection.
Funding
Funding not disclosed
Founders
Product
Problem
The accurate and timely detection of melanoma and other skin cancers is often hindered by the limited availability of dermatologists and the potential for human error in visual skin lesion analysis. This can lead to delayed diagnoses and treatment, negatively impacting patient outcomes.
Solution
Kāhu is developing an AI-powered platform designed to enhance the early detection of melanoma and other skin cancers. By analyzing dermatological images from a large database of skin lesions, the platform aims to provide healthcare professionals with an additional layer of support in clinical diagnosis and management. Kāhu's technology is being developed in collaboration with Molemap Ltd, leveraging their extensive collection of high-quality dermatological images. The platform is designed with patient safety as a core principle, ensuring that the AI's insights are evidence-backed and clinically validated. Kāhu intends to support doctors in making more informed decisions, ultimately improving patient outcomes in skin cancer detection.
Target Audience
The primary target audience includes dermatologists, general practitioners, and other healthcare professionals involved in skin cancer screening and diagnosis.
Features
- AI-driven analysis of dermatological images for skin lesion detection
- Access to a large database of classified skin lesion images
- Technology developed in collaboration with dermatologists and skin cancer experts
- Focus on early detection of melanoma and other skin cancers
- Designed to support healthcare professionals in clinical diagnosis and management